Mergers & Acquisitions ·
Galmed Pharmaceuticals Ltd. reported a net loss of $1.9 million for the three months ended March 31, 2026, compared to…
GLMDGalmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. reported a net loss of $1.9 million for the three months ended March 31, 2026, compared to $1.1 million in the prior year period. The company completed the acquisition of Colospan Ltd. on June 22, 2026, for an aggregate cash consideration of $3.3 million and a performance-based earnout of up to $2.0 million. Galmed Pharmaceuticals is a biopharmaceutical company focused on the development of liver disease treatments.